Home » Topics » BioWorld Science

BioWorld Science
RSS

Takeda set to begin voluntary and conditional public takeover bid for TiGenix

April 25, 2018

Curadev Pharma targets ACSS2 for antitumor agents

April 25, 2018

Boehringer Ingelheim and Topas Therapeutics enter research agreement

April 25, 2018

First patient enrolled in phase III trial of topical ocular reproxalap

April 25, 2018

Results on sodium oxybate presented in pediatric patients with narcolepsy type 1

April 25, 2018

Third Rock Ventures launches Cedilla Therapeutics

April 25, 2018

Completion of phase I study of tozuleristide in pediatric brain tumor surgery

April 25, 2018

Nektar, Takeda to evaluate NKTR-214 in combination with TAK-659

April 25, 2018

Initiation of phase Ib trial of CMP-001 plus atezolizumab in anti-PD-1/PD-L1 resistant NSCLC

April 25, 2018

Procalcitonin predicts malignant cerebral edema after massive cerebral infarction

April 25, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...